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Abstract 
The objective of the study was to assess the prevalence and clinical features of incidentally 
discovered clinically non-functioning pituitary adenoma (CNFPA) and to analyze its natural 
history. A multicenter retrospective study in patients diagnosed with incidental CNFPA 
periodically followed-up in 3 specialized neuroendocrinology units from 1992 to 2015 was 
performed. Out of a total of 189 CNFPA patients, 57 cases (30.1%; 29 women; age at diagnosis 
55.8±16.7 years) were incidental. Most patients (n=55, 96.5%) were diagnosed by magnetic 
resonance imaging (MRI). A sum of 71.9% (n=41) were macroadenomas; 2 of them (3.5%) were 
giant adenomas (≥4 cm). Patients with macroadenomas were older than those with 
microadenomas (59.5±16.7 vs. 46.4±18.1 years, p=0.007). Macroadenomas were more common 
in men (85.7% vs. 58.6%, p=0.023). Twenty-eight patients (49.1%) showed suprasellar extension; 
of these, 19 were accompanied by chiasmatic compression. Hypopituitarism was present in 14 
(24.6%) patients; which was partial in 13 patients (22.8%) and complete in one patient (1.8%). 
The gonadal axis was the most frequently affected (n=13, 22.8%). Twenty four patients (42.1%) 
underwent surgery. Of the non-operated patients, 26 patients could be evaluated morphologically 
after a median follow-up of 15.5 months (interquartile range, 5.7–32.7 months). No significant 
changes were found in the maximum tumor diameter at the end of follow-up (1.2±0.6 vs 
1.2±0.7 cm). The majority of CNFPAs evaluated (n=23, 88.5%) did not show any changes in size. 
In 2 cases (7.7%) tumor size decreased, and in one patient (3.8%) increased. In our series of 
CNFPA patients, approximately one-third were incidental. These tumors were diagnosed by MRI 
preferably from the 5th decade of life without sex predilection. Most of them were 
macroadenomas, more commonly diagnosed in men and at an older age, compared to 
microadenomas. The suprasellar extension with chiasmatic compression and hypopituitarism 
were frequent at diagnosis. Most of the non-operated incidental CNFPAs remain with stable 
tumor size over time, growth being an unusual event. 
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Introduction 
Pituitary adenoma (PA) is a neuroendocrine tumor diagnosed with increasing 
frequency [1, 2]. At present, it is considered as the third neoplasm of the central nervous 
system, following to meningioma and glioma [3, 4]. The majority of PAs are 
functioning, mainly prolactinomas, and approximately one third of the patients have 
clinically non-functioning pituitary adenomas (CNFPAs) [5, 6]. 
 
The increase in the use of imaging techniques in recent years, mainly magnetic 
resonance imaging (MRI), has been associated with a noteworthy increase in the 
incidence of pituitary lesions incidentally discovered, also named pituitary 
incidentalomas (PIs) [7–9]. Its prevalence is very variable and ranges from 11 % in 
autopsy studies to 4–20 % and 10–38 % in computed tomography (CT) and MRI 
studies, respectively [10]. More than 90 % of these PIs are pituitary adenomas, usually 
CNFPAs, and about 9 % are craniopharyngiomas or Rathke’s cleft cysts [9, 11, 12]. 
 
CNFPAs in adults are usually macroadenomas (≥ 1 cm) and frequently are 
associated with compressive symptoms derived from local involvement of neighboring 
structures with neuro-ophthalmological symptoms and/or hypopituitarism. However, 
macro-CN-FPAs can be also incidental tumors discovered in imaging study. On the 
contrary, micro-CNFPAs (< 1 cm) are almost always incidentally discovered lesions.  
 
Although the prevalence of PIs has significantly increased in re-cent years, data 
regarding the prevalence and natural history of CNFPAs incidentally discovered remain 
sparse [6, 7, 10, 13–15]. Therefore, our aims were 1) to know the prevalence of 
incidental CNFPAs from a cohort of CNFPA patients, 2) to assess the clinical features 
of these incidental CNFPAs, and 3) to analyze its natural history in non-operated 
patients. 
Patients and Methods 
Patients 
A multicenter retrospective study in patients diagnosed with incidental CNFPA and 
periodically followed-up in 3 specialized Neuroendocrinology Units from 3 different 
tertiary care Spanish hospitals in the last 4 decades (from 1992 to 2015) was performed.  
 
Patient distribution according to location was Hospital Ramón y Cajal, Madrid, n = 
27 (47.4 %); Hospital Universitario A Coruña, A Coruña, n= 18 (31 %); and Hospital de 
Bellvitge, L’Hospitalet de Llobregat, Barcelona, n= 12 (21.1 %). Median (interquartile 
range) follow-up was 25 months (7–127 months). 
Methods 
PI was considered when a previously unsuspected pituitary lesion was found in a 
casual way after performing an imaging study for reasons unrelated to pituitary disease. 
Incidental CNFPA was de-fined as a PI compatible with PA in imaging study in the 
absence of clinical evidence of pituitary hormonal overproduction in non-operated 
patients or the histological demonstration of PA in those patients underwent surgery. All 
those patients with imaging study compatible with craniopharyngioma and Rahtke’s 
cleft cyst were excluded. We also excluded non-operated patients treated with 
radiotherapy and/or medical treatment (dopaminergic agonists and/or somatostatin 
analogues). 
  
For every patient, clinical parameters (age at diagnosis, sex, and main complaint at 
presentation), endocrine dysfunction (the presence of hypopituitarism, number of axes 
involved, and hyperprolactinemia), ophthalmological symptoms, imaging study (MRI 
and/or CT scan findings), and change in tumor size were recorded. 
 
The surgical criteria were individualized for each patient according to medical 
criterion, clinical situation, and acceptance of surgery by the patient. These criteria were 
based primarily on the mass effect of the tumor associated with neuro-ophthalmological 
involvement with or without pituitary hypofunction. 
 
All procedures performed in the present study were in accordance with the ethical 
standards of the institutional committee and with the 1964 Helsinki declaration. 
Statistical analysis 
For quantitative variables, results are expressed as mean ± SD for normally 
distributed data, and as median (interquartile range) for nonparametric data. Adjustment 
to normal distribution was tested by the Kolmogorov test. Categorical variables are 
described as percentages. For comparisons of means between 2 groups of sub-jects the 
Student’s t-test was used for normally distributed data, and the Mann–Whitney test was 
employed for nonparametric data. For categorical comparisons the χ2test or the Fisher 
exact test were used. Differences were considered significant when p < 0.05. 
Results 
Clinical and hormonal data 
Of a total of 189 patients with CNFPA, 57 cases (30.1 %) [29 women (50.9 %); age 
at diagnosis 55.8 ± 16.7 years (range, 18–83)] were incidental. Males were older than 
females (59.3 ± 14.6 vs. 52.4 ± 18.2 years, ns). Of incidental CNFPAs, 43.9 % were 
older than 60 years, 40.3 % belonged to the age group of 40–60 years and 15.8 % were 
younger than 40 years. Clinical features of the patients according to clinical form 
presentation at diagnosis are summarized in ▶Table 1. Distribution of 57 patients with 
incidental CNF-PAs according to sex and adenoma size at diagnosis is shown in ▶Fig. 1. 
 
 
 
  
▶Table 1. Clinical features of 189 patients with clinically non-functioning pituitary adenomas according to 
clinical form presentation at diagnosis. 
 Incidental n = 57 (30.1 %) Non-incidental n = 132 (69.9 %) 
   
Clinical data at diagnosis   
Age (mean ± SD) (years) 55.8 ± 16.7 51.5 ± 15.8 
Sex (M/F), n (%) 28 (49.1 %)/29 (50.9 %) 62 (47 %)/70 (53 %) 
Age groups, n (%)   
< 40 years 9 (15.8 %) 27 (20.4 %) 
40–60 years 23 (40.3 %) 69 (52.3 %) 
> 60 years 25 (43.9) 36 (27.3 %) 
Abnormal visual field, n (%) 18 (31.5 %) 60 (45.4 %) * 
Endocrinological study, n (%)   
Hypopituitarism 14 (24.6 %) 49 (37.1 %) * 
Partial 13 (22.8 %) 41.8 (32 %) * 
Complete 1 (1.8 %) 7 (5.3 %) 
Hyperprolactinemia 14 (24.6 %) 32 (24.2 %) 
Central hypogonadism 13 (22.8 %) 37 (28.0 %) 
Central hypothyroidism 9 (15.8 %) 24 (18.2 %) 
Secondary adrenal insufficiency 7 (12.3 %) 26 (19.7 %) 
GH deficiency 3 (5.3 %) 18 (13.6 %) 
Imaging study, n (%)   
MRI 55 (96.5 %) 120 (90.9 %) 
CT 2 (3.5 %) 12 (9.1 %) 
Suprasellar extension 28 (49.1 %) 92 (69.7 %) ** 
Chiasma compression 19 (33.3 %) 79 (59.8 %) *** 
Cavernous sinuses invasion 16 (28.1 %) 48 (36.4 %) 
Tumor related data   
Macroadenoma, n (%) 41 (71.9 %) 116 (87.9 %) * 
Giant adenoma, n (%) 2 (3.5 %) 17 (12.9 %) * 
Microadenoma, n (%) 16 (28.1 %) 16 (12.1 %) * 
Maximum tumor diameter (cm) 1.6 ± 0.9 2.5 ± 1.3 * 
   
 
* p < 0.05; * * p < 0.01; * * * p < 0.001 non-incidental vs. incidental CNFPA. 
 
 
 
▶Fig. 1. Distribution of 57 patients with incidental 
clinically non-functioning pituitary adenomas according 
to sex and adenoma size at diagnosis. 
 
 
  
Most patients (n = 55, 96.5 %) were diagnosed by MRI and the remaining by CT. 
Hyperprolactinemia was present in 14 patients (24.6 %). The median prolactin level was 
11.1 ng/ml (7–21.1 ng/ml; range 2.6–95 ng/ml). Hyperprolactinemic patients showed a 
higher tumor size than normoprolactinemic patients (2.3 ± 0.9 cm vs. 1.4 ± 0.9 cm, p = 
0.006). The percentage of patients underwent surgery was significantly higher in 
hyperprolactinemic than in normoprolactinemic patients (73.3 % vs. 28.5 %, p = 0.002). 
No significant difference in the prevalence of hyperprolactinemia between inci-dental 
and non-incidental CNFPAs was found (▶Table 1). 
 
Hypopituitarism was present in 14 (24.6 %) patients; which was partial in 13 
patients (22.8 %) and complete in one patient (1.8 %). The gonadal axis was the most 
frequently affected (n= 13, 22.8 %). Incidental CNFPA patients who underwent surgery 
showed a higher prevalence of hormonal involvement of the gonadal (p = 0.008), 
adrenal (p = 0.034), and thyroid (p = 0.028) axes compared to those not operated. 
Lastly, incidental CNFPAs were associated with less involvement of pituitary function 
than those with non-incidental CNFPAs (▶Table 1). 
Tumor-related data 
Forty one patients (71.9 %) had macroadenomas; 2 of them (3.5 %) were giant 
adenomas (≥ 4 cm). Patients with macroadenomas were older than those with 
microadenomas (59.5 ± 16.7 vs. 46.4 ± 18.1 years, p = 0.007). Macroadenomas were 
more common in men (85.7 % vs. 58.6 %, p = 0.023) (▶Fig. 1).Mean maximum tumor 
diameter was 1.6 ± 0.9 cm and was significantly higher in males than in females (2,0 ± 
1.0 vs. 1.3 ± 0.8 cm; p =0.015) (▶Fig. 2). Incidental CNFPAs were significantly smaller 
in size and less invasive than non-incidental CNFPAs (▶Table 1). 
 
 
 
▶Fig. 2. Maximum tumor diameter at diagnosis 
according to sex in 57 patients with incidental clinically 
non-functioning pituitary adenomas. 
About half of the patients (n= 28; 49.1 %) showed suprasellar extension; of these, 19 
(33.3 %) were accompanied by chiasmatic compression. Abnormal visual field 
examination was common (n = 18, 31.5 %) although its prevalence was lower than that 
observed in non-incidental CNFPAs (45.4 %, p = 0.028). Invasion of the cavernous 
sinuses was present in 28.1 % (n = 16). 
  
Clinical follow-up 
Twenty four patients (42.1 %) underwent surgery. Hypopituitarism (p = 0.002), 
central hypogonadism (p = 0.004), secondary adrenal insufficiency (p = 0.013), central 
hypothyroidism (p = 0.019), and hyperprolactinemia (p = 0.002) were more common in 
these patients than in those not surgically treated. Immunohistochemical study for 
anterior pituitary hormones was performed in the tumor samples of the patients. 
Hormones most frequently detected were gonadotropins (FSH [n = 5, 20.8%] and LH [n 
= 4, 16.7%]), followed by PRL (n= 2, 8.3 %), ACTH (n= 1, 4.2 %), and GH (n= 1, 4.2 
%). None of the patient showed TSH positive staining. In 9 patients (37.5 %), 
immunohistochemical staining was negative. 
 
Of the 33 non-operated patients, 26 patients (45.6 %) could be evaluated after a 
median follow-up of 15.5 months (interquartile range, 5.7–32.7 months). No significant 
changes were found in the maximum tumor diameter at the end of follow-up (1.2 ± 0.6 
vs. 1.2 ± 0.7 cm; NS). The majority of CNFPAs evaluated (n = 23, 88.5 %) did not 
show any changes in size. In 2 cases (7.7 %), tumor size de-creased (reduction of 
maximum diameter > 2 mm) and in one patient (3.8 %) increased (increase of maximal 
diameter > 2 mm; initial maximal tumor diameter 1.0 cm; 1.3 cm increase in a 30-year-
old male after 76 months of follow-up) (▶Fig. 3). 
 
 
 
▶Fig. 3. Spontaneous evolution of pituitary adenoma size 
in 26 patients with incidental clinically non-functioning 
pituitary adenomas after a median follow-up of 15.5 
months (interquartile range, 5.7–32.7 months). The black 
thick line joins the points representing the mean 
maximum tumor diameter at diagnosis and at the last 
visit. 
  
Discussion 
The present study shows that in our environment CNFPAs were incidentally 
discovered in about one third of cases. In spite of being tumors discovered incidentally, 
a detailed clinical, analytical, ophthalmologic and morphological study reveals that 
approximately one third shows chiasmatic compression and about a quarter is associated 
with pituitary hypofunction, although hypopituitarism is usually partial. These 
incidental CNFPAs are usually macroadenomas (approximately 3 quarters) commonly 
discovered at around 60 years of age. The prevalence of tumor growth after a roughly 1 
year of follow up in non-operated incidental CNFPAs is very low (~4 %). 
 
Most studies that have analyzed PIs have considered all types of pituitary lesions 
incidentally found in the imaging study [13]. In this setting, they are not homogeneous 
series of patients and, therefore, the results are not applicable to a particular pathology. 
One of the main differences between our study and the rest of the studies carried out on 
PIs is that we excluded all those patients with other pituitary lesions such as 
craniopharyngiomas, pituitary cysts, and functioning pituitary adenomas, therefore only 
patients with a clinical diagnosis of CNFPA were considered. 
 
It has been reported that about half (45 %) of PIs are macroincidentalomas [10]. In 
our series of 189 CNFPA patients, approximately one third (n= 57) were incidentally 
found. Most of these patients (n = 41, 71.9 %) had macroadenomas. This prevalence, 
although elevated, was significantly lower than that observed in non-incidental CNFPAs 
(87.9 %). 
 
Mean age at diagnosis of PIs is around 47 years, with a slightly higher age in males 
compared to females [16]. In our cohort of incidental CNFPA patients age at diagnosis 
was higher not only to that reported in PIs, but also to the non-incidental CNFPAs, al-
though in the latter case statistical significance was not reached (56 years vs. 51 years, 
respectively). It is possible that the different etiologies of PIs and the presence of 
symptoms associated with non-incidental CNFPAs would explain these differences. As 
reported in PIs [16, 17], macroadenomas were more frequently found in males with 
incidental CNFPAs. The contrary occurred with microadenomas, which were more 
commonly seen in women. It is possible that CNFPAs in men have a higher 
proliferative activity and tumor aggressiveness showing a different nature and biological 
behavior compared to women, as it has been suggested in other pituitary tumors such as 
prolactinomas [18]. 
 
MRI is considered as the gold standard for initial imaging diagnosis of sellar lesions 
providing more detailed images relative to CT. In our study, the great majority of 
incidental CNFPAs were discovered by this technique. Less than 5 % of these tumors 
were dis-covered by CT preferably in the hospital emergency services where CT is the 
preferred imaging technique. Some preoperative MRI appearances of pituitary 
adenomas have been associated with CNFPA such as lowered T1 relaxation rate and 
increased tumor extension into adjacent anatomic compartments and sinus invasion 
[19]. 
 
Hyperprolactinemia is a common finding in CNFPAs. Its prevalence in patients with 
histologically proven non-functioning adenomas is 25–65 % [20]. In a retrospective 
study of 226 CNFPA patients, median prolactin level was 18 ng/ml (range 0.8–73.6 
ng/ml) [21]. Although the differentiation between CNFPA with hyperprolactinemia and 
prolactinoma is sometimes difficult, it has been suggested that prolactin levels < 100 
ng/ml associated with older age, extrasellar extension with visual defects and the 
presence of hypo-functioning GH axis can be considered suggestive of CNFPA [22]. 
Our incidental CNFPA patients showed similar prolactin levels (11.1 ng/ml) and similar 
prevalence (24.6 %) of hyperprolactinemia than those reported by others in non-
incidental CNFPA patients [20], suggesting that hyperprolactinemia is a common 
finding in patients with CNFAs regardless of clinical presentation, that is, incidental or 
symptomatic, where significant differences in the prevalence of hyperprolactinemia 
were not found. 
 
  
Multiple observational and retrospective studies performed in CNFPA patients have 
shown a prevalence of partial and complete hypopituitarism of 37–85 % and 6–29 %, 
respectively [20]. In our series these percentages were similar or slightly lower for non-
incidental CNFPAs (32 % and 5.3 %, respectively). In relation to incidental CNFPAs, 
we found a significantly lower prevalence of partial hypopituitarism compared with 
non-incidental CPNAs. In spite of this, this prevalence was high (22.8 %) indicating 
that, in many cases, the symptoms associated with hormonal deficiency are un-noticed 
or non-referred by the patient. GH deficiency and central hypogonadism have been 
reported to be the most commonly affected axes in CNFPAs, followed by corticotropin 
and thyrotropin deficiencies [20]. In our series of incidental CNFPAs, gonadotropin 
deficiency was the endocrine pituitary hypofunction more commonly reported, followed 
by thyrotropin and corticotropin deficiencies, and finally GH deficiency. These results 
were very similar to those found in non-incidental CNFPAs, indicating that there does 
not seem to be a relationship between the type of hormonal pituitary deficiency and the 
clinical presentation form (symptomatic or incidental) of CNFPAs. 
 
Based on the available clinical evidence, mainly retrospective and prospective 
observational cohort studies, pituitary surgery is the treatment of choice in symptomatic 
CNFPA patients and in those who show tumor growth during follow-up. Surgery is 
accompanied by a significant reduction in tumor size, and a significant improvement in 
both visual and pituitary functions [23]. It is note-worthy that in our series of incidental 
CNFPAs, a high percentage (42.1 %) was treated with surgery suggesting a high 
prevalence of non-perceived symptoms (neuroophtalmologic and/or endocrine 
symptoms) in these patients. Lastly, a significant higher prevalence of pituitary 
hypofunction in incidental CNFPAs underwent surgery compared with not-surgically 
treated patients was found. 
 
Few studies have evaluated the natural history of CNFPAs. An analysis of the 
natural history of 513 CNFPAs in 10 series of patients during a 2 to 7-year follow-up 
showed that most of them did not modify tumor size (83.1 % and 63.2 % for micro- and 
macroadenomas, respectively). An increase in tumor size was reported in 10.6 % of the 
microadenomas and 24.1 % of the macroadenomas, while a spontaneous reduction of 
the tumor volume was reported in 6.3 % and 12.7 % of the micro- and macroadenomas, 
respectively [14]. However, not all patients in this series were incidental; many of them 
did not undergo surgery due to major comorbidities or refusal of surgery by the patient. 
To the best of our knowledge, our series is the first to analyze only patients with 
incidental CNFPAs with-out surgical criteria. In this case the majority of tumors 
remained stable (88.5 %), a minority decreased (7.7 %), and tumor growth was 
exceptional (3.8 %). These findings suggest that clinical follow-up with endocrine 
evaluation and imaging studies is a reason-able option in these patients. 
 
In conclusion, CNFPAs are diagnosed incidentally in about one third of cases, 
usually by MRI preferably from the 5th decade of life without sex predilection. Most of 
them are macroadenomas, more commonly diagnosed in men and at an older age, 
compared to microadenomas. Suprasellar extension with chiasmatic compression and 
visual field defects and hypopituitarism are frequent at diagnosis. Most of the non-
operated incidental CNFPAs remain with stable tumor size over time, growth being an 
unusual event. 
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